Who is sponsoring NCT03672201?

NCT03672201 is sponsored by Centre for Addiction and Mental Health.

What drugs are being tested in NCT03672201?

Interventions in NCT03672201: Non-Pharmacological Intervention, Pharmacological Intervention.

What condition does NCT03672201 study?

NCT03672201 studies Alzheimer's Disease, Alzheimer Dementia (AD), Aggression.

Is NCT03672201 still recruiting?

NCT03672201 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT03672201: StaN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia

Active, enrolled NA Last updated 13 April 2026

What this trial tests

NA trial testing Non-Pharmacological Intervention in Alzheimer's Disease in 187 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 November 2018

Primary endpoint
31 March 2023

31 December 2027

Quick facts

Lead sponsor	Centre for Addiction and Mental Health
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	187
Start date	1 November 2018
Primary completion	31 March 2023
Estimated completion	31 December 2027
Sites	6 locations across Canada

Drugs / interventions tested

Non-Pharmacological Intervention
Pharmacological Intervention — full drug profile →

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →
Alzheimer Dementia (AD) — all drugs for Alzheimer Dementia (AD) →
Aggression — all drugs for Aggression →

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

50 and older, any sex, with Alzheimer's Disease or Alzheimer Dementia (AD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The object of this study to evaluation an Integrated Care Pathway (ICP) to treat Aggression and Agitation in Alzheimer's disease (AD-AA). The ICP is an algorithmic approach to use psychotropic medications and non-pharmacological interventions based on standardized assessments which fosters measurement-based decision making. This study will assess the efficacy of the ICP to treat AD-AA and its impact on inappropriate use of medications in inpatient settings and Long-Term Care Facilities (LTCF). The investigators will enroll and randomize 220 participants with AD-AA (110 inpatient and 110 LTCFs) to ICP vs. Treatment As Usual. Further, this study will also examine the impact of the ICP on caregiver burden and undertake a cost-effectiveness analysis of the ICP for patients with AD-AA.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Fall Risk and Psychotropic and General Medication Use in Dementia with Neuropsychiatric Symptoms
Gok S, Amarin S, Schoer N, Burhan A, et al · · 2025
Sex Differences in Phenomenology of Behavioral and Psychological Symptoms of Dementia.
Choudhury S, Colman S, Chu L, Davies SJC, et al · · 2025 · PMID 41037500 · DOI 10.1159/000548713
The impact of lifetime excessive alcohol use on behavioural and psychological symptoms of dementia.
Tavakoli E, Niciforos E, Amid P, Cuperfain AB, et al · · 2025 · PMID 40794901 · DOI 10.1093/alcalc/agaf048
Standardizing Care for Agitation in Alzheimer’ Dementia: Results from a Randomized Controlled Trial of an Integrated Care Pathway versus Usual Care ‐The StaN trial
Kumar S, Burhan A, Chu L, Colman S, et al · · 2024

Verify or expand the search:

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03672201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03672201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing